TECH · BIO-TECHNE Corp
$72.55
-0.07 (-0.10%)
At close · Oct 23
Return incl. dividend (before tax)
Market Cap
$11.38B
Shares
156.82M
Volume · Oct 23
1.9M
Avg daily vol (3M)
3.03M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$72.55
Open$72.60
Day$72.55–72.63
52W close$43.30–72.64
Avg vol 30d3.1M
Short int7.4M · 4.7% float · 2.1d
Short vol58%
Last earningsAug 12, 2026
DataJan 2020–Oct 2026
Filing10-K · Aug 24
Up next
Next earnings call
Nov 11, 2026
Est · unconfirmed
· in 2 wks
filed Aug 24, 2026
call held May 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.22B
Trailing 12 months
Net income (TTM)
$181.86M
Trailing 12 months
Revenue growth YoY
+1.3%
Year over year
Operating margin
20.7%
Trailing 12 months
P / E (TTM)
62.5
Trailing earnings · reciprocal yield 1.6%
FCF yield
2.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
0.4%
Trailing 12 months
Shares change YoY
-1.0%
Year over year · fewer shares
Price change (1Y)
+9.8%
Trailing year
Short interest
4.7%
Latest settlement · 2.1 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Low
Market backdrop
VIX 19.5 · elevated
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+15%
above
Price vs 50-day avg
+0%
above
RSI (14)
55
neutral
MACD trend
Negative
52-week position
100%
near high
Momentum
relative strength
1-month return
0%
trailing
6-month return
+33%
trailing
YTD return
+23%
this year
Relative strength
+27%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $72 › 200d $63 — 50d above 200d
Institutional flow
Distributing
109 of 601 funds reported for Sep 30 · net -762.4K sh shares · +11 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.71% of float · ▲ +11.4% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
601 holders — near 3-yr high, broad support
Squeeze score
57
elevated · 0–100
Fundamentals
Revenue growth
−0%
Y/Y
Gross margin
66%
expanding
EPS growth
+152%
Y/Y
Free cash flow
$263.2M
Valuation
P/E 62.5
in line
Buyback
$405.0M
remaining
Quant / Vol
risk profile
Volatility
44%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
0.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Feb 2, 2021
in five years
Ella business
$200M – $300M
for a long time
Growth
at least 25%
this year
Official NIH budget
at least 3%
a year
Demand for proteins in the workflow
at least $10M
Needs
at least $10M
annually
GMP proteins
at least $40M
Projected volume
at least 95%
the next few years
Growth
at least 30%
our five-year plan
This technology generating
$200M – $300M
the next couple of years
Total comfy performance
at least 40%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+15%
Bullish
Price vs 50-day avg
+0%
Bullish
RSI (14)
55
Neutral
MACD trend
Negative
Bearish
52-week position
100%
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $72 › 200d $63 — 50d above 200d
Institutional flow
Distributing
109 of 601 funds reported for Sep 30 · net -762.4K sh shares · +11 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.71% of float · ▲ +11.4% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
601 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $43
Now $73 · 100%
Range high $73
vs 200-day avg +15%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Capital additions | $28.9M | fiscal 2026 filing | — |
| Cash from operations | $292.1M | fiscal 2026 filing | — |
| Diagnostics and Spatial Biology segment gross margin percentage | 55.2% | Year Ended June 30, 2026 filing | — |
| Earnings before taxes - Adjusted non-GAAP | $390.39M | Year Ended June 30, 2026 filing | — |
| new products introduced | 1,900 | fiscal 2026 filing | — |
| Non-GAAP adjusted net earnings non-GAAP | $303.34M | Year Ended June 30, 2026 filing | — |
| Protein Sciences segment gross margin percentage | 75% | Year Ended June 30, 2026 filing | — |
| Adjusted EBITDA non-GAAP | $431.98M | Year Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net earnings 181.86M
+5.41M Net interest expense (income)
+97.36M Depreciation and amortization
+58.82M Income taxes
+9.96M Amortization of Wilson Wolf intangible assets
+8.57M Acquisition related expenses and other
+5.51M Certain litigation charges
+42.64M Stock-based compensation, inclusive of employer taxes
+21.06M Restructuring and restructuring-related costs
+5.01M Investment loss and other non-operating loss
-6.79M Impairment (Recovery) of assets held-for-sale
+2.57M Impact of business held-for-sale
= Adjusted EBITDA 431.98M
|
|||
| Adjusted EPS non-GAAP | $1.93 | Full Year FY2026 | — |
| Adjusted gross margin percentage non-GAAP | 69.6% | Year Ended June 30, 2026 | — |
| Adjusted operating income non-GAAP | $386.1M | Full Year FY2026 | — |
GAAP → non-GAAP reconciliationGAAP Operating income - GAAP $251.89M
+$61.18M Amortization of intangibles
+$7.99M Acquisition related expenses and other
+$5.51M Certain litigation charges
+$42.64M Stock-based compensation, inclusive of employer taxes
+$21.06M Restructuring and restructuring-related costs
-$6.79M Impairment (Recovery) of assets held-for-sale
+$2.57M Impact of business held-for-sale
= Adjusted operating income $386.05M
|
|||
| Adjusted operating margin percentage non-GAAP | 31.9% | Year Ended June 30, 2026 | — |
| Diagnostics and Spatial Biology segment operating margin | 11.2% | Full Year FY2026 | — |
| Non-GAAP adjusted tax rate non-GAAP | 22.3% | Year Ended June 30, 2026 | — |
| Organic revenue growth non-GAAP | 3% | Q4 FY2026 | — |
| Protein Sciences segment operating margin | 41.1% | Full Year FY2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TECH
this stock
BIO-TECHNE Corp
|
$11.38B | +23.4% | -0.4% | 62.5 | 4.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.80B | +15.6% | +46.2% | 30.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.88B | +4.3% | +20.8% | 19.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.89B | +578.5% | +4.3% | — | 7.7% |
|
CSLLY
Csl Ltd
|
$66.42B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TECH | 0.0% | -0.1% | +32.5% | +0.1% | +23.4% |
| SPY | -0.4% | -1.5% | +5.8% | -0.4% | +11.5% |
| vs SPY | +0.4% | +1.4% | +26.7% | +0.5% | +11.9% |
Capital returns
Latest dividend
$0.08
/ share · ex Aug 24, 2026
Paid (TTM)
$0.32
/ share · 4 payouts
Dividend yield (TTM, derived)
0.44%
Buyback program
· as of Mar 31, 2026
Authorized
—
Spent (derived)
—
Remaining
$405.00M
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
842023
CUSIP
09073M104
13F (30d)
99 filings
94 filers
Visit website
Investor relations